The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...

The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted ...

Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an ...

With many patients utilizing medical cannabis, it is important for nurses to be aware of potential drug-drug interactions, an ...

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...

Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...